

NAGI SNAPSHOT GUIDES

Accelerating Early Toxicology Testing with novel NAMs

Chose the best candidates in early preclinical studies, from setup to actionable insights.



The Challenge

Current early toxicology bottlenecks:

- *In vitro* assays lack whole-organism insights.
- Mammalian testing is costly, slow, and raises ethical concerns.


Need: A middle ground that is predictive, scalable, and sustainable.

The ideal scenario? Being able to get multiple, insightful datapoints in one-shot assay as early as possible in your pipeline and with a full organism model.

A Multi-Endpoint, One-Shot Approach to Toxicity Screening

C. elegans screening with SydLab™ One provides a rapid, cost-effective, and reliable alternative that bridges the gap between *in vitro* cell-based assays and traditional mammalian testing, offering a whole-organism approach to toxicity screening.

- **Whole-organism Predictivity:** Bridge the gap between *in vitro* and *in vivo*.
- **Animal Reduction:** Practical application of a NAMs technology and model¹.
- **Holistic Toxicity Insights:** Early multi-endpoint readouts accelerate decision-making.
- **Sustainable Science:** Fewer animals, faster data, same scientific rigor.



¹ Hunt, P. R. (2017) The *C. elegans* model in toxicity testing. *J. Appl. Toxicol.*, 37: 50–59. doi: 10.1002/jat.3357.

Why *C. elegans*?

Conserved Genes & Pathways

C. elegans shares ~60–80% of its genes and signaling pathways with humans, making it a valuable model for studying human health and toxicity.

Predictive Accuracy

High sensitivity in identifying toxic compounds, especially in developmental toxicity studies, with overall balanced accuracy of ~84%.

Ethical & Cost-Effective

Reduces downstream numbers on mammalian testing, aligning with the 3Rs principle.

Comprehensive Analysis

Monitors multiple biological endpoints, including growth, reproduction, and behavior, providing a holistic view of toxicity

The Approach: *C. elegans* as a Complementary Tool in Multi-tiered Toxicity Testing Enhancing Risk Identification and Reducing Animal Testing

Screening Phase NAMs: *C. elegans*, organoids, and zebrafish models efficiently filter out low-risk compounds.


SydLab™ One: Automated culture in a highly consistent manner:

Temperature




Nutrient Supply

Nagi™
Chips



Mammalian Testing Phase:
Ensure a comprehensive view before proceeding to mammalian studies.



More than
~ 50% reduction
in low-risk
compounds



More than
30% decrease in
mammalian
testing

Nagi Bioscience's technology

A **game-changer** for toxicology by integrating *C. elegans* into toxicology workflows, Nagi Bioscience advances science while promoting ethical testing practices.

Our solutions enhance **predictive accuracy**, **streamline chemical screening**, and pave the way for a **sustainable, animal-reduced** future in toxicology.

Nagi™ DART: How we answer your safety questions

We applied the Nagi™ DART assay to blindly assess 21 benchmark chemicals (at 5 concentrations) with known toxic effects or no effects.

Balanced accuracy of 85.7%

21 benchmark chemicals with known Reprotox effects, either positive or negative, were tested in blind on the microfluidic platform SydLab™ One.

5 concentrations for each chemical (1mM, 333µM, 111µM, 37µM and 12µM) were tested and compared to the negative control (DMSO 1%). Three technical repeats were executed, each chemical being tested twice. No-Observed-Adverse-Effect Level (NOAEL) was determined and their toxicity profile described.

	Maximum length	Growth dynamic	Fertility	Sexual maturity	Egg accum.	Embryo survival	Larvae emergence	Larvae accum.	Progeny growth	Conclusion	Toxic profil in vertebrate	Predictive
5-Fluorouracil										Reprotoxicity	Toxic	Yes
Ascorbic acid										No AE Observed	Negative	Yes
Benzalkonium chl.										Maternal AE	Toxic	Yes
Bisphenol A										Maternal AE	Toxic	Yes
Busulfan										Reprotoxicity	Toxic	Yes
Dexamethasone										Maternal AE	Toxic	Yes
Diphenhydramine										No AE Observed	Negative	Yes
Fingolimod										Maternal AE	Toxic	Yes
Hydroxyurea										Maternal AE	Toxic	Yes
Imatinib										Maternal AE	Toxic	Yes
Lithium chloride										No AE Observed	Toxic	No
Methotrexate										Embryotoxicity effect	Toxic	Yes
Methoxyacetic acid										Maternal AE	Toxic	Yes
Paraquat										No AE Observed	Toxic	No
Penicilin G										No AE Observed	Negative	Yes
Phenytoin										Reprotoxicity	Toxic	Yes
Progesterone										Maternal AE	Negative	No
Sodium Chloride										No AE Observed	Negative	Yes
Tetracycline										Maternal AE	Toxic	Yes
Thalidomide										Maternal AE	Toxic	Yes
Thiamazole										Reprotoxicity	Toxic	Yes


6 concentrations vs solvent (µM):



3 technical replicates per experiment
2 independent experiments


Let's look closer: AI-driven multi-phenotypic analysis

Effects of Paraquat




Paraquat caused significant maternal adverse effects at high doses (NOAEL: 2.5 mM) and pronounced reproductive toxicity at lower doses (NOAEL: 0.16 mM).

Effects of 5FU



5-FU exhibited no maternal adverse effects at the tested doses but demonstrated strong reproductive toxicity at intermediate doses (NOAEL: 50 µM).

Throughput and Translational Impact

	<i>in vitro</i>	 nagi bioscience	Zebrafish	Mice
Throughput	> 384 drugs/month	384 drugs/month	30-40 drugs/month	3-5 drugs/month
Translational value	Low	High	High	High

The numbers of drugs per month/year refer to the number of compounds that can be tested in 30 days, without technical repetitions or controls.

**Explore the Swiss knife
platform for safety and
efficacy testing**



**Accelerate your research
with Nagi Bioscience**

Let's connect

info@nagibio.ch